Chan L - Search Results

1

Mitosis targeting in non-small lung cancer cells by inhibition of PAD4.

Wu X, Chan L, Zhu D, Pang Y, Jin M, Wang Y, Wang W. Wu X, et al. Among authors: chan l. Heliyon. 2024 Mar 8;10(6):e27313. doi: 10.1016/j.heliyon.2024.e27313. eCollection 2024 Mar 30. Heliyon. 2024. PMID: 38496857 Free PMC article.

2

High-Dimensional Immune Profiling by Mass Cytometry Revealed the Circulating Immune Cell Landscape in Patients With Intracranial Aneurysm.

Ge P, Liu C, Chan L, Pang Y, Li H, Zhang Q, Ye X, Wang J, Wang R, Zhang Y, Wang W, Zhang D, Zhao J. Ge P, et al. Among authors: chan l. Front Immunol. 2022 Jun 27;13:922000. doi: 10.3389/fimmu.2022.922000. eCollection 2022. Front Immunol. 2022. PMID: 35833148 Free PMC article.

3

Genistein-induced mitochondrial dysfunction and FOXO3a/PUMA expression in non-small lung cancer cells.

Chan L, Pang Y, Wang Y, Zhu D, Taledaohan A, Jia Y, Zhao L, Wang W. Chan L, et al. Pharm Biol. 2022 Dec;60(1):1876-1883. doi: 10.1080/13880209.2022.2123933. Pharm Biol. 2022. PMID: 36200643 Free PMC article.

4

mRNA sequencing and CyTOF analysis revealed ASPP2 altered the response patterns of hepatocellular carcinoma HepG2 cells to usnic acid.

Wang Y, Yan Y, Huo Y, Pang Y, Chan L, Wang S, Chen D, Lin D, Wang W. Wang Y, et al. Among authors: chan l. Naunyn Schmiedebergs Arch Pharmacol. 2023 Aug;396(8):1847-1856. doi: 10.1007/s00210-023-02428-2. Epub 2023 Mar 6. Naunyn Schmiedebergs Arch Pharmacol. 2023. PMID: 36877271

5

Targeting mitochondrial dynamics by AZD5363 in triple-negative breast cancer MDA-MB-231 cell-derived spheres.

Fu Y, Dong W, Xu Y, Li L, Yu X, Pang Y, Chan L, Deng Y, Qian C. Fu Y, et al. Among authors: chan l. Naunyn Schmiedebergs Arch Pharmacol. 2023 Oct;396(10):2545-2553. doi: 10.1007/s00210-023-02477-7. Epub 2023 Apr 24. Naunyn Schmiedebergs Arch Pharmacol. 2023. PMID: 37093249 Free PMC article.

6

The ruthenium complex assists in nuclear targeting and selective killing of tumor cells.

Lu Y, Zhu D, Chan L, Hu B, Tuohan M, Li L, Wang W, Wang Y. Lu Y, et al. Among authors: chan l. Nanoscale. 2023 Jul 13;15(27):11529-11543. doi: 10.1039/d3nr02707d. Nanoscale. 2023. PMID: 37358379

7

The combination of the HDAC1 inhibitor SAHA and doxorubicin has synergic efficacy in triple negative breast cancer in vivo.

Pang Y, Shi R, Chan L, Lu Y, Zhu D, Liu T, Yan M, Wang Y, Wang W. Pang Y, et al. Among authors: chan l. Pharmacol Res. 2023 Oct;196:106926. doi: 10.1016/j.phrs.2023.106926. Epub 2023 Sep 15. Pharmacol Res. 2023. PMID: 37716547 Free article.

8

Mass cytometry revealed the circulating immune cell landscape across different Suzuki stages of Moyamoya disease.

Liu C, Ge P, Zhang B, Chan L, Pang Y, Tao C, Li J, He Q, Liu W, Mou S, Zheng Z, Zhao Z, Sun W, Zhang Q, Wang R, Zhang Y, Wang W, Zhang D, Zhao J. Liu C, et al. Among authors: chan l. Immunol Res. 2024 Aug;72(4):654-664. doi: 10.1007/s12026-024-09464-x. Epub 2024 Feb 20. Immunol Res. 2024. PMID: 38376705 Free PMC article.

9

CyTOF analysis revealed platelet heterogeneity in breast cancer patients received T-DM1 treatment.

Ma J, Pang Y, Shang Y, Xie C, Xu X, Chan L, Zhang Z, Wang W. Ma J, et al. Among authors: chan l. Clin Immunol. 2024 Jun;263:110227. doi: 10.1016/j.clim.2024.110227. Epub 2024 Apr 21. Clin Immunol. 2024. PMID: 38643891

10

T cells immune imbalance presents in patients with multiple intracranial aneurysms.

Tao C, Liu C, Ge P, Chan L, Pang Y, Li J, He Q, Liu W, Mou S, Zheng Z, Zhang B, Zhao Z, Sun W, Zhang Q, Wang R, Zhang Y, Wang W, Zhang D, Zhao J. Tao C, et al. Among authors: chan l. Clin Exp Immunol. 2025 Jan 21;219(1):uxae058. doi: 10.1093/cei/uxae058. Clin Exp Immunol. 2025. PMID: 38990891

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,160 results

Search Page

Filters